At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABCL AbCellera Biologics
Market Closed 01-30 16:00:00 EST
3.62
-0.24
-6.22%
盘后3.65
+0.03+0.83%
19:58 EST
High3.83Low3.59Vol4.31M
Open3.80D1 Closing3.86Amplitude6.22%
Mkt Cap1.08BTradable Cap733.95MTotal Shares299.34M
T/O15.92MT/O Rate2.13%Tradable Shares202.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets
Simply Wall St.  ·  01-30 16:38
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets
Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Dow Jones  ·  01-23
Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Abcellera Biologics Inc. to Announce Full Year 2025 Financial Results
Reuters  ·  01-23
Abcellera Biologics Inc. to Announce Full Year 2025 Financial Results
AbCellera Biologics Showcases Progress in Antibody Drug Development and Clinical Pipeline
Reuters  ·  01-15
AbCellera Biologics Showcases Progress in Antibody Drug Development and Clinical Pipeline
AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate
MT Newswires Live  ·  01-12
AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate
AbCellera doses first patients in Phase 2 portion of ABCL635 trial
TIPRANKS  ·  01-12
AbCellera doses first patients in Phase 2 portion of ABCL635 trial
BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug
Reuters  ·  01-12
BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug
AbCellera Begins Phase 2 Trial of ABCL635 for Menopausal Vasomotor Symptoms
Reuters  ·  01-12
AbCellera Begins Phase 2 Trial of ABCL635 for Menopausal Vasomotor Symptoms
Abcellera Announces First Patients Dosed in Phase 2 Portion of Its Phase 1/2 Clinical Trial of Abcl635 for the Treatment of Vasomotor Symptoms Due to Menopause
THOMSON REUTERS  ·  01-12
Abcellera Announces First Patients Dosed in Phase 2 Portion of Its Phase 1/2 Clinical Trial of Abcl635 for the Treatment of Vasomotor Symptoms Due to Menopause
Abcellera Biologics Inc - Anticipates Top-Line Results in Q3 2026
THOMSON REUTERS  ·  01-12
Abcellera Biologics Inc - Anticipates Top-Line Results in Q3 2026
AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake
Reuters  ·  2025-12-20
AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires Live  ·  2025-12-19
Sector Update: Health Care Stocks Rise Late Afternoon
AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement
MT Newswires Live  ·  2025-12-18
AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement
BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation
Reuters  ·  2025-12-18
BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation
Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties
THOMSON REUTERS  ·  2025-12-18
Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties
Abcellera and Bruker Reach Global Settlement of Patent Litigation
THOMSON REUTERS  ·  2025-12-18
Abcellera and Bruker Reach Global Settlement of Patent Litigation
AbCellera to Present at J.P. Morgan Healthcare Conference
Reuters  ·  2025-12-09
AbCellera to Present at J.P. Morgan Healthcare Conference
Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials
Simply Wall St.  ·  2025-12-06
Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials
Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares
Reuters  ·  2025-11-27
Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares
Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress
Simply Wall St.  ·  2025-11-26
Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress

Introduction

Company Name.
AbCellera Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Issue price:
--